cbdMD, Inc.

YCBD

US12482W4087

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:00 2026-04-10 pm EDT			5-day change	1st Jan Change
0.6801 ^USD	+4.01%		-7.22%	-49.62%

Apr. 06	Hawkeye Systems, Inc. Announces President and Directorate Appointments	CI
Apr. 01	CbdMD, Inc. Announces Launch of Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare	CI

Earnings Flash (YCBD) CBDMD Posts Q4 Revenue $24.2M

Published on 12/22/2023 at 04:08 pm EST - Modified on 12/22/2023 at 04:09 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about cbdMD, Inc.

Apr. 06	Hawkeye Systems, Inc. Announces President and Directorate Appointments	CI
Apr. 01	CbdMD, Inc. Announces Launch of Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare	CI
Feb. 17	CbdMD, Inc., Q1 2026 Earnings Call, Feb 17, 2026
Feb. 17	CbdMD, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
Feb. 02	Cbdmd, Inc.'S Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum	CI
Jan. 29	CbdMD, Inc. Strengthens Regulatory Science Platform to Support Emerging Regulatory Cannabinoid Evaluation Pathways	CI
Jan. 14	cbdMD announces strategic acquisition of Bluebird Botanicals	RE
Jan. 13	CbdMD, Inc. acquired assets of Gaia Botanicals, LLC for $1 million.	CI
Dec. 19	CbdMD, Inc., Q4 2025 Earnings Call, Dec 19, 2025
Dec. 19	CbdMD, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
Dec. 19	Investors Hope for Rate Cut Following Subdued Inflation as US Futures Mixed in Friday's Premarket Session	MT
Dec. 19	CbdMD Insider Sold Shares Worth $1,276,842, According to a Recent SEC Filing	MT
Dec. 19	Wall Street Set to Open Little Changed as Investors Await Home Sales, Consumer Sentiment Data	MT
Dec. 19	Investors Hope for Rate Cut Following Subdued Inflation as US Futures Mixed in Friday's Premarket Session	MT
Dec. 18	CbdMD, Inc. Auditor Raises 'Going Concern' Doubt	CI

cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.

Employees

Sector

Pharmaceuticals

More about the company